NX PharmaGen
Curated by SignalDiagnostic technology for detection of circulating exosomes.
Overview
NX PharmaGen develops diagnostic technology for the detection of circulating exosomes. Its proprietary NeXosome platform uses proteomics to detects an array of biomarkers shed by tumors or placental tissue that have been enclosed within blood-based exosomes or microvesicles. Nx PharmaGen has two subsidiary companies. NxPrenatal uses the NeXosome platform to detect the risk of preterm birth in women by analyzing maternal blood for specific placental and fetal exosomes. NxDevelopment Corp. has developed Gliolan, a real time diagnostic imaging agent that has been approved in 30 countries ex- US for detection of glioblastoma multiforme.
Key facts
- Founded
- 2010
- Headquarters
- Louisville, United States
- Stage
- Sign up to view
- Industry
- Life Sciences Technology
Business model
- 3 products and services
- Sign up to view